- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01197482
Inhaled Steroids and Control of Severe Asthma (INHALE)
Inhaled Steroids and Control of Severe Asthma: Comparison of the AKITA Technology Versus Conventional MDI (INHALE)
Investigational device: AKITA 2 device versus conventional metered-dose inhaler (MDI)
Objectives: To explore if inhalative fluticasone application by means of the AKITA technology would result in a better symptom control in patients with severe persistent asthma as compared to inhalative application of fluticasone by a conventional MDI.
Study design: open label, cross-over (one AKITA, one MDI arm)
Patients: 20 Patients with severe persistent asthma
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
-
Giessen, Duitsland, 35392
- Justus-Liebig-University Giessen
-
Greifenstein, Duitsland
- Lungenfachklinik Waldhof Elgershausen
-
Marburg, Duitsland
- Philipps-Universität Marburg
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Severe persistent asthma bronchiale with diagnosis according to the criteria of the Global Initiative for Asthma (GINA) executive summary
- Treatment with at least inhaled corticosteroids (ICS) and long acting b agonists (LABA)
- Evidence of inflammatory triggered form of asthma with at least one of the following:
- sensitization to typical aerogenous allergens
- increased Serum IgE levels
- Eosinophilia in peripheral blood
- Proven Eosinophilia in sputum differential (> 3%) in the previous 2 years
- at least 2 exacerbations of asthma within the previous 24 months leading to unscheduled presentation at a health care provider and/or systemic corticosteroid
- Signed informed consent
- Requirements of the local ethics committee are met
Exclusion Criteria:
- Acute exacerbation of asthma within the last 6 weeks Rtot > 350% predicted capillary pO2 < 60mmHG, pCo2 > 50mmHG near fatal asthma or anaphylaxis in history
- Age ≤ 18 and > 80 years
- Active smoking or > 15 pack-years former smoking
- Oral steroid treatment with a prednisolon-equivalent dose exceeding 10 mg per day
- Pregnancy, nursing females
- Female without use of effective contraceptive method
- Treatment with investigational drugs over the past 30 days or during the course of the trial
- Severe and uncontrolled gastroesophageal reflux disease
- Ongoing psychiatric disorder
- Treatment with systemic corticosteroids for any reason other than asthma
- Other active lung diseases
- Medical history of other uncontrolled diseases 3 months prior randomization (e.g. infections, coronary heart diseases and metabolic diseases)
- Any history of malignancy requiring ongoing treatment and/or limiting life-expectancy
- Clinically significant abnormalities in electrocardiogram (ECG) or laboratory exams
- Asthma related to non-steroidal anti-inflammatory drug (NSAID)
- Insulin dependent diabetes mellitus
- Cataract
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Case-control
- Tijdsperspectieven: Prospectief
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Asthma control
Tijdsspanne: 38 weeks
|
Changes in asthma control, measured by Juniper Asthma Control Questionnaire during the 16 week treatment period in AKITA versus MDI based steroid application.
Physician will assess level of asthma control in accordance with criteria from Gaining Optimal Asthma Control (GOAL) study.
|
38 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Standardized asthma related quality of life questionnaire (AQLQs)
Tijdsspanne: 38 weeks
|
AQLQs will be completed at screening, randomization, crossover and at end of study
|
38 weeks
|
Steroid, fluticasone and reliever medication use
Tijdsspanne: 38 weeks
|
doses of systemic steroids and fluticasone dosage will be assessed and documented.
Frequency of use of reliever medication will be summed from patient's diary and documented.
|
38 weeks
|
Lung function
Tijdsspanne: 38 weeks
|
Pulmonary function tests (PFT) will be performed and lung function will be assessed by means of spirometry and body plethysmography.
|
38 weeks
|
Diffusing capacity for carbon monoxide
Tijdsspanne: 38 weeks
|
Diffusing capacity for carbon monoxide will be assessed at rest and holding breath at full inspiration.
|
38 weeks
|
Capillary blood gas analysis
Tijdsspanne: 38 weeks
|
Capillary blood gas analysis will be obtained from the arterialized ear lobe.
|
38 weeks
|
Measurement of Fractional Concentration of Nitric Oxide in Exhaled Air (feNO)
Tijdsspanne: 38 weeks
|
feNO will be assessed at each visit.
Measurements will be performed following the recommendations of the American Thoracic Society (ATS) and the European Respiratory Society (ERS).
|
38 weeks
|
Cell differential in induced sputa
Tijdsspanne: 1 day
|
Induced sputum will be obtained at screening if not done within the previous 2 years.
|
1 day
|
Adrenal function
Tijdsspanne: 38 weeks
|
Determination of the fraction of urinary cortisol has been used for screening of adrenal hypo- or hyperfunction and showed to be as effective as 24 hour urinary free cortisol excretion.
Urine samples will be obtained at baseline, randomization, crossover and end of study.Values will be recorded.
|
38 weeks
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Andreas Guenther, MD, University of Gießen
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- AZ 109/09
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Ernstig aanhoudend astma
-
Hanan JafarVoltooidPersistent hoornvliesepitheeldefectJordanië
-
Combangio, IncKala Pharmaceuticals, Inc.WervingPersistent hoornvliesepitheeldefectVerenigde Staten
-
Kiora Pharmaceuticals, Inc.VoltooidPersistent hoornvliesepitheeldefectMexico
-
Noveome Biotherapeutics, formerly StemnionVoltooidPersistent hoornvliesepitheeldefectVerenigde Staten
-
University of Colorado, DenverVoltooidZiekte van SeverVerenigde Staten
-
Amber Ophthalmics, Inc.WervingPersistent hoornvliesepitheeldefectVerenigde Staten
-
Noveome Biotherapeutics, formerly StemnionIQVIA BiotechBeëindigdPersistent hoornvliesepitheeldefectVerenigde Staten
-
Santen Pharmaceutical Co., Ltd.VoltooidPersistent hoornvliesepitheeldefectJapan
-
Acibadem UniversityVoltooidGang | Ziekte van Sever | Calcaneale apofysitisKalkoen
-
Fundacion PodoactivaVoltooidZiekte van Sever | Calcaneale apofysitisSpanje